Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
BEAM regimen (BCNU, etoposide, cytarabine, and melphalan) is the most commonly used
conditioning regimen for relapsed/refractory lymphoma patients needing autologous stem cell
transplantation. Since these components are all effective in myeloma and bortezomib has shown
promising results in the transplant setting, here the investigators propose a phase II study
to investigate the combination of bortezomib and BEAM as a new conditioning regimen for
patients who relapse or progress after the first autologous transplantation and for whom a
second autologous transplant is considered.